Rezdiffra™ (resmetirom): a THR-β agonist for non-alcoholic steatohepatitis.
作者信息
Brisnovali Niki F, Haney Connor, Goedeke Leigh
机构信息
Department of Medicine (Cardiology), Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Medicine (Cardiology), Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine (Endocrinology), Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
出版信息
Trends Pharmacol Sci. 2024 Nov;45(11):1081-1082. doi: 10.1016/j.tips.2024.08.009. Epub 2024 Sep 19.
Abstract
摘要
相似文献
1
Rezdiffra™ (resmetirom): a THR-β agonist for non-alcoholic steatohepatitis.
Trends Pharmacol Sci. 2024 Nov;45(11):1081-1082. doi: 10.1016/j.tips.2024.08.009. Epub 2024 Sep 19.
2
Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
J Med Econ. 2024 Jan-Dec;27(1):1108-1118. doi: 10.1080/13696998.2024.2393952. Epub 2024 Aug 22.
3
Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics.
Clin Res Hepatol Gastroenterol. 2024 Aug;48(7):102377. doi: 10.1016/j.clinre.2024.102377. Epub 2024 May 19.
4
Resmetirom: First Approval.
Drugs. 2024 Jun;84(6):729-735. doi: 10.1007/s40265-024-02045-0. Epub 2024 May 21.
5
Resmetirom (Rezdiffra) for metabolic dysfunction-associated steatohepatitis.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):65-66. doi: 10.58347/tml.2024.1701a.
6
Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.
touchREV Endocrinol. 2023 May;19(1):60-70. doi: 10.17925/EE.2023.19.1.60. Epub 2023 May 1.
7
Estimation of the Eligible Population For Resmetirom Among Adults in the United States for Treatment of Non-Cirrhotic NASH with Moderate-to-Advanced Liver Fibrosis.
Adv Ther. 2024 Nov;41(11):4172-4190. doi: 10.1007/s12325-024-02989-5. Epub 2024 Sep 18.
8
Resmetirom (Rezdiffra) for the Treatment of Noncirrhotic Nonalcoholic Steatohepatitis With Moderate to Advanced Fibrosis.
Am Fam Physician. 2024 Sep;110(3):313-314.
9
Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis.
Br J Pharmacol. 2021 Jun;178(12):2412-2423. doi: 10.1111/bph.15427. Epub 2021 Apr 6.
10
Efficacy and safety of resmetirom among patients with non-alcoholic steatohepatitis: a systematic review and meta-analysis.
Ann Med Surg (Lond). 2024 Jul 15;86(9):5447-5454. doi: 10.1097/MS9.0000000000002314. eCollection 2024 Sep.
引用本文的文献
1
Flavone C-Glycosides from L. Attenuate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) via Multi-Pathway Regulations.
Nutrients. 2025 Jul 28;17(15):2456. doi: 10.3390/nu17152456.
2
Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024.
Pharmaceuticals (Basel). 2025 May 15;18(5):729. doi: 10.3390/ph18050729.
3
In Situ Assembly of Fluorogenic RNA for Screening Natural Anti-Liver Fibrosis Products via Dynamic Visualization of COL1A1 mRNA.
Adv Sci (Weinh). 2025 Aug;12(30):e02850. doi: 10.1002/advs.202502850. Epub 2025 May 23.
4
Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom.
Curr Issues Mol Biol. 2025 Feb 27;47(3):154. doi: 10.3390/cimb47030154.
5
Dapansutrile Regulates Mitochondrial Oxidative Stress and Reduces Hepatic Lipid Accumulation in Diabetic Mice.
Curr Issues Mol Biol. 2025 Feb 25;47(3):148. doi: 10.3390/cimb47030148.
本文引用的文献
1
Resmetirom: First Approval.
Drugs. 2024 Jun;84(6):729-735. doi: 10.1007/s40265-024-02045-0. Epub 2024 May 21.
2
Metabolic Messengers: Thyroid Hormones.
Nat Metab. 2024 Apr;6(4):639-650. doi: 10.1038/s42255-024-00986-0. Epub 2024 Apr 26.
3
New and emerging treatments for metabolic dysfunction-associated steatohepatitis.
Cell Metab. 2024 Jun 4;36(6):1430. doi: 10.1016/j.cmet.2024.04.016. Epub 2024 Apr 25.
4
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
5
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.
Nat Med. 2023 Nov;29(11):2919-2928. doi: 10.1038/s41591-023-02603-1. Epub 2023 Oct 16.
6
Cell-Specific Transport and Thyroid Hormone Receptor Isoform Selectivity Account for Hepatocyte-Targeted Thyromimetic Action of MGL-3196.
Int J Mol Sci. 2022 Nov 8;23(22):13714. doi: 10.3390/ijms232213714.
7
Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH).
PLoS One. 2020 Dec 11;15(12):e0240338. doi: 10.1371/journal.pone.0240338. eCollection 2020.
8
Thyroid Hormone Signaling and the Liver.
Hepatology. 2020 Aug;72(2):742-752. doi: 10.1002/hep.31296.
9
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia.
J Med Chem. 2014 May 22;57(10):3912-23. doi: 10.1021/jm4019299. Epub 2014 Apr 8.
Zotero 插件